Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investor Conference. The company, which is developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, will engage in a fireside chat on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.
Investors and interested parties can access the live webcast of the fireside chat through the Investors tab on www.acumenpharm.com. The webcast will remain archived on the website for 90 days following the event, providing an opportunity for those unable to attend the live session to catch up on the discussion.
Acumen Pharmaceuticals (NASDAQ: ABOS), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione al 26° Congresso Annuale Globale degli Investitori H.C. Wainwright. L'azienda, che sta sviluppando una nuova terapia mirata a oligomeri tossici solubili di beta amiloide per il trattamento dell'Alzheimer, parteciperà a un incontro informale martedì 10 settembre 2024, alle 13:30 ET.
Gli investitori e le parti interessate possono accedere al webcast in diretta dell'incontro attraverso la sezione Investitori su www.acumenpharm.com. Il webcast rimarrà archiviato sul sito web per 90 giorni dopo l'evento, offrendo a coloro che non possono partecipare alla sessione dal vivo la possibilità di recuperare la discussione.
Acumen Pharmaceuticals (NASDAQ: ABOS), una empresa biofarmacéutica en fase clínica, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversores H.C. Wainwright. La empresa, que está desarrollando una nueva terapia dirigida a oligómeros tóxicos solubles de beta-amiloide para el tratamiento de la enfermedad de Alzheimer, participará en un chat informal el martes, 10 de septiembre de 2024, a la 1:30 p.m. ET.
Los inversores y las partes interesadas pueden acceder a la transmisión en vivo del chat a través de la pestaña de Inversores en www.acumenpharm.com. La retransmisión permanecerá archivada en el sitio web durante 90 días después del evento, ofreciendo la oportunidad a quienes no puedan asistir a la sesión en vivo de ponerse al día con la discusión.
Acumen Pharmaceuticals (NASDAQ: ABOS), 임상 단계의 생명공학 회사가 H.C. Wainwright 제26회 연례 글로벌 투자자 회의에 참여한다고 발표했습니다. 알츠하이머병 치료를 위한 독성 수용성 아밀로이드 베타 올리고머를 표적으로 하는 새로운 치료제를 개발 중인 이 회사는 2024년 9월 10일 화요일 오후 1시 30분 ET에 비공식 대화에 참여할 예정입니다.
투자자와 관심 있는 관계자는 www.acumenpharm.com의 투자자 탭을 통해 비공식 대화의 실시간 웹 방송에 접근할 수 있습니다. 웹 방송은 이벤트 종료 후 90일 동안 웹사이트에 아카이브되어 있어, 생중계에 참석할 수 없는 분들이 토론 내용을 따라잡을 수 있는 기회를 제공합니다.
Acumen Pharmaceuticals (NASDAQ: ABOS), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale des Investisseurs H.C. Wainwright. L'entreprise, qui développe une nouvelle thérapie ciblant les oligomères bêta-amyloïdes solubles et toxiques pour le traitement de la maladie d'Alzheimer, participera à une discussion informelle le mardi 10 septembre 2024, à 13h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct de la discussion via l'onglet Investisseurs sur www.acumenpharm.com. La diffusion restera archivée sur le site pendant 90 jours après l'événement, offrant ainsi aux personnes qui ne peuvent pas assister à la session en direct la possibilité de se mettre à jour sur la discussion.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 26. jährlich globalen Investorenkonferenz von H.C. Wainwright angekündigt. Das Unternehmen, das eine neuartige Therapie zur Bekämpfung von giftigen löslichen Beta-Amyloid-Oligomeren zur Behandlung von Alzheimer entwickelt, wird am Dienstag, den 10. September 2024, um 13:30 Uhr ET an einem informellen Gespräch teilnehmen.
Investoren und Interessierte können über den Investoren-Tab auf www.acumenpharm.com auf die Live-Übertragung des Gesprächs zugreifen. Die Übertragung bleibt 90 Tage nach der Veranstaltung auf der Website archiviert, um denjenigen, die nicht an der Live-Sitzung teilnehmen können, die Möglichkeit zu geben, die Diskussion nachzuholen.
- None.
- None.
NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investor Conference on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.
The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) participating in the H.C. Wainwright Global Investor Conference?
What is Acumen Pharmaceuticals (ABOS) developing?
How can investors access Acumen Pharmaceuticals' (ABOS) fireside chat at the conference?
What stage of development is Acumen Pharmaceuticals (ABOS) currently in?
